Oxford Biomedica Solutions
Mary Rose Amato is an experienced professional in the field of quality compliance and risk management, currently serving as Associate Director of Quality Compliance at Oxford Biomedica since June 2022. Prior to this role, Amato spent nearly a decade at Sanofi, where responsibilities included Associate Director of Risk Management and various positions in quality compliance, culminating as Principal Compliance Specialist. Earlier experience includes a role as Contract Test Services Analyst at Associates of Cape Cod, Inc., and QC Chemistry Analyst at Sanofi. With a robust background in compliance and quality control, Mary Rose Amato has developed expertise in managing quality-related risks in the biopharmaceutical industry.
This person is not in any offices
Oxford Biomedica Solutions
Oxford Biomedica Solutions, LLC is the high-performing, full scope Adeno-Associated Virus (AAV) vector Manufacturing and Innovation joint venture of Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), and Homology Medicines, Inc. (Nasdaq: FIXX) (“Homology”). We offer global pharmaceutical and biotechnology clients innovative manufacturing expertise in AAV and lentiviral-based cell and gene therapies. Oxford Biomedica Solutions LLC provides access to Homology’s innovative and proven end-to-end AAV manufacturing capabilities, and customers also benefit from technical synergies brought in by the Group’s know-how in lentiviral vector manufacturing. This collaborative and complementary vector-based approach has the potential to accelerate our collective mission to improve patients’ lives worldwide.